Participant flow16

How many started, completed or left each group, period by period.

1 to 16 of 16

Period	Milestone	Group	Participants
Overall Study	STARTED	Placebo	32
Overall Study	STARTED	Brodalumab 210 mg	32
Overall Study	STARTED	Brodalumab 350 mg	33
Overall Study	STARTED	Brodalumab 700 mg	33
Overall Study	Received Study Drug	Placebo	32
Overall Study	Received Study Drug	Brodalumab 210 mg	31
Overall Study	Received Study Drug	Brodalumab 350 mg	32
Overall Study	Received Study Drug	Brodalumab 700 mg	33
Overall Study	COMPLETED	Placebo	28
Overall Study	COMPLETED	Brodalumab 210 mg	19
Overall Study	COMPLETED	Brodalumab 350 mg	21
Overall Study	COMPLETED	Brodalumab 700 mg	16
Overall Study	NOT COMPLETED	Placebo	4
Overall Study	NOT COMPLETED	Brodalumab 210 mg	13
Overall Study	NOT COMPLETED	Brodalumab 350 mg	12
Overall Study	NOT COMPLETED	Brodalumab 700 mg	17

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT01150890/flow